Keystone Financial Group
Position in RXRX — Recursion Pharmaceuticals, Inc.
CIK 1729299
LEXINGTON, KY
Position in RXRX
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$49,120
-$8,140 QoQ
Shares Held
16,000
+14.3% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in RXRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Keystone Financial Group holds $1,451,239 across 7 Biotechnology names. RXRX ranks #6 (3.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PRME |
Prime Medicine, Inc.
|
166,010 | $577,714 | |
| 2 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
8,000 | $501,600 | |
| 3 | CRBU |
Caribou Biosciences, Inc.
|
80,475 | $152,902 | |
| 4 | IBRX |
ImmunityBio, Inc.
|
10,000 | $76,700 | |
| 5 | LRMR |
Larimar Therapeutics, Inc.
|
13,000 | $58,500 | |
| 6 | RXRX |
Recursion Pharmaceuticals, Inc.
This page
|
16,000 | $49,120 | |
| 7 | EDIT |
Editas Medicine, Inc.
|
14,050 | $34,703 |
All Filings in RXRX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $49,120 | 16,000 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $57,260 | 14,000 | Shares | Sole | 2026-02-06 | |
| No filing history on record for this holder in this stock. | ||||||